Challenges With Triplet Regimens for the Treatment of Hematologic Malignancies
Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events.
Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events (AEs).
Adding a new drug to any combination can be tricky due to the potential increase in AEs with these regimens. For example, the combination of ipilimumab (Yervoy) and a PD-1 inhibitor increases toxicity, which would only increase more when adding a third drug. However, Skarbnik says that is the cost to pay for the efficacy that has been found with this particular combination.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
